U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression

Why is UnitedHealth under Medicare fraud investigation? How did Trump’s Middle East visit boost AI deals? What caused Foot Locker’s stock to surge recently? Why is Tesla’s chairwoman paid more than peers? How will Calif. budget deficit affect immigrant health care? Why is CoreWeave’s revenue soaring after IPO? What impact will GOP tax bill have on Americans? Why are Starbucks employees striking over dress code? How did Boeing secure its largest-ever jet order?

U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression

news.abbvie.com/2025-05-14-U-S-FDA-Approves-EMRELIS-TM-telisotuzumab-vedotin-tllv-for-Adults-With-Previously-Treated-Advanced-Non-Small-Cell-Lung-Cancer-NSCLC-With-High-c-Met-Protein-Overexpression

EMRELIS is the first and only treatment approved for previously treated advanced NSCLC patients with high c-Met protein overexpression who often face poor prognosis and have limited treatment options
– Lung cancer remains the leading cause of cancer-related deaths throughout the…

This story appeared on news.abbvie.com, 2025-05-14 20:38:43.779000.